BOT 16.9% 38.0¢ botanix pharmaceuticals ltd

Ann: BTX 1503 Acne Phase 2 Study Results Presentation, page-548

  1. 231 Posts.
    lightbulb Created with Sketch. 38
    The FDA will not be concerned by efficacy they will only be concerned by safety and the drug we know has a very good safety profile. The efficacy will be now determined by the Phase 3 trial. The difficulty is we need a CR to fund a phase 3 trial with enough power. I know they have cash at hand but I think they will be using this for the other irons they have in the fire but a good question to ask at the AGM
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.